Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-401237

General Counsel and Secretary sold 10,400 shares at $60.24 ($626,460)

  • General Counsel and Secretary acquired 10,400 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
KASINGER JAMES R. General Counsel and Secretary 2026-09-22 Option exercise 10b5-1 +10,400 $13.62 $141,648 105,184 D: show line 1 in the form
KASINGER JAMES R. General Counsel and Secretary 2026-09-22 Sale 10b5-1 −10,400 $60.24 $626,460 94,784 D: show line 2 in the form
Open-market sales · 10,400 sh · avg $60.24 · $626,460

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
KASINGER JAMES R. General Counsel and Secretary 2026-09-22 Option exercise · Stock Option (Right to Buy) 10b5-1 −10,400 83,232 D: show line 3 in the form
Loading xslF345X06/ownership.xml…